Quidel announced it completed the acquisition of the InflammaDry and AdenoPlus diagnostic businesses from RPS Diagnostics for approximately $14 million in cash.
The InflammaDry and AdenoPlus products are rapid, lateral-flow based, POC products for the detection of infectious and inflammatory diseases and conditions of the eye. InflammaDry is the only test that detects elevated levels of MMP-9, a key inflammatory marker for dry eye. AdenoPlus is a test on market today that differentiates between a viral and bacterial infection of acute conjunctivitis (pink eye). Both products utilize innovative patented technology, are also CE marked, FDA-cleared, CLIA-waived, and complement Quidel’s existing rapid diagnostic testing solutions. Manufacturing for both products will be transferred to Quidel’s San Diego facility in the near term.
“InflammaDry and AdenoPlus products represent a solid growth opportunity in adjacent markets for Quidel,” Douglas Bryant, president and chief executive officer of Quidel Corporation, said in a company news release. “The addition of these two product lines will further strengthen our position in CLIA-waived diagnostic testing at the Point-of-Care.”
InflammaDry and AdenoPlus revenues will be reflected in Quidel’s Immunoassay revenue category.